CPC C07K 16/2878 (2013.01) [A61K 31/454 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/6801 (2017.08); A61K 47/6849 (2017.08); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] | 7 Claims |
1. An isolated antibody that specifically binds to CD3, wherein the antibody comprises:
(a) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 332, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 340, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 342;
(b) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 411, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(c) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 415, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 430, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 342;
(d) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 332, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 335, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 430, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 446;
(e) a VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 421, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 423, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 341, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 432;
(f) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 427, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 429, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 433, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 434;
(g) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 447, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 449, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 431, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 452, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 453;
(h) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 437;
(i) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 438;
(j) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 437;
(k) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(l) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 440, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(m) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439;
(n) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 402, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 404, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 435, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439; or
(o) VH CDR1 comprising the amino acid sequence shown in SEQ ID NO: 407, a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 409, a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 406, a VL CDR1 comprising the amino acid sequence shown in SEQ ID NO: 441, a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 436, and a VL CDR3 comprising the amino acid sequence shown in SEQ ID NO: 439.
|